NewsBenzingaCardiol Therapeutics anuncia avances en la inscripción y planes para expandir su ensayo de fase III MAVERIC para evaluar CardiolRx en la reducción del riesgo de recurrencia en pacientes con pericarditis recurrente Cardiol Therapeutics anuncia avances en la inscripción y planes para expandir su ensayo de fase III MAVERIC para evaluar CardiolRx en la reducción del riesgo de recurrencia en pacientes con pericarditis recurrente Benzinga 2026.09.23 10:02 (GMT+0) Open on Benzinga Other news Barclays Maintains Equal-Weight on Exelon, Lowers Price Target to $44 The FTC Allows Publicis’ LiveRamp Acquisition To Move Forward With Safeguards To Protect Customer Data And Fair Competition. Citizens Financial Analysts Slash Their Forecasts Following Q3 Results Barclays Maintains Overweight on Evergy, Lowers Price Target to $86 Mastercard Brings Its Fraud-Fighting Tools to Stablecoin Payments Barclays Maintains Overweight on Entergy, Lowers Price Target to $115
The FTC Allows Publicis’ LiveRamp Acquisition To Move Forward With Safeguards To Protect Customer Data And Fair Competition.
